Seres Therapeutics - 在首次临床试验中,80%的Ser-155受试者在第15天实现无免疫抑制应答

美股速递
Jul 08

Seres Therapeutics宣布,其候选药物Ser-155在一项首次临床试验中取得了积极结果。数据显示,高达80%的受试者在给药后第15天即实现了无需使用免疫抑制剂的治疗应答。这一早期数据展现了该疗法在调控免疫反应方面的潜力,为后续开发奠定了重要基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10